| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BCAM; AU; LU; MSK19 |
| Entrez GeneID | 4059 |
| clone | 8C4E6 |
| WB Predicted band size | 67.4kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD239 (AA: extra 32-197) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD239抗体的3篇参考文献示例(请注意：由于CD239并非广泛使用的标准命名，可能与特定研究或非标准抗原相关，以下内容为模拟示例，建议根据实际研究方向核实)：
1. **文献名称**: **"CD239 as a novel biomarker in metastatic breast cancer: implications for antibody therapy"**
**作者**: Li Y, et al.
**摘要**: 该研究首次报道CD239在乳腺癌细胞表面的高表达，并开发了靶向CD239的单克隆抗体。实验表明，该抗体通过阻断肿瘤细胞迁移信号通路，显著抑制小鼠模型中转移灶的形成。
2. **文献名称**: **"Structural characterization of anti-CD239 antibody and its binding mechanism to laminin receptors"**
**作者**: Gupta R, et al.
**摘要**: 通过X射线晶体学解析了CD239抗体的结构，揭示其特异性识别细胞表面层粘连蛋白受体(CD239)的表位，为开发基于此抗体的癌症诊断试剂提供了分子基础。
3. **文献名称**: **"Anti-CD239 antibody-drug conjugate exhibits potent antitumor activity in multiple myeloma"**
**作者**: Wang H, et al.
**摘要**: 研究构建了CD239抗体-药物偶联物(ADC)，在多发性骨髓瘤模型中显示出强效的肿瘤杀伤作用，且对正常细胞毒性较低，提示其作为靶向治疗的潜力。
**注意**：实际文献需通过PubMed或Google Scholar检索确认。若CD239指向特定病原体(如疟疾研究中Duffy抗原/CD234)，可能需要调整关键词(如"Duffy antigen antibody")。建议结合具体研究背景进一步验证。
**Background of CD239 Antibody**
CD239 antibody targets the CD239 antigen, also known as the Lutheran glycoprotein (Lu), a cell surface protein encoded by the *BCAM* gene. CD239 is a member of the immunoglobulin superfamily (IgSF) and functions as a receptor for laminin, a key component of the extracellular matrix. Primarily expressed on red blood cells (RBCs) and certain epithelial/endothelial cells, it plays roles in cell adhesion, signaling, and maintaining tissue integrity.
CD239 gained attention due to its involvement in pathological conditions. In sickle cell disease (SCD), CD239 mediates abnormal adhesion of sickled RBCs to vascular endothelium, contributing to vaso-occlusive crises. This makes it a potential therapeutic target; blocking CD239-laminin interactions may alleviate complications. Additionally, CD239 is overexpressed in some cancers, including ovarian and colorectal malignancies, where it may promote tumor progression and metastasis.
Antibodies against CD239 serve as vital research tools for studying its biological functions and disease associations. Monoclonal antibodies, in particular, enable precise detection of CD239 expression in tissues or blood, aiding in diagnostic and prognostic evaluations. Therapeutic applications are under exploration, with efforts to develop antibody-based inhibitors to disrupt pathogenic CD239 interactions in SCD or cancer.
Overall, CD239 antibodies bridge fundamental research and clinical innovation, offering insights into cell adhesion mechanisms and pathways for targeted therapies in hematological and oncological disorders.
×
